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Abstract
An increasing body of evidence indicates that accumulation of soluble oligomeric assemblies of b-amyloid polypeptide (Ab)
play a key role in Alzheimer’s disease (AD) pathology. Specifically, 56 kDa oligomeric species were shown to be correlated
with impaired cognitive function in AD model mice. Several reports have documented the inhibition of Ab plaque formation
by compounds from natural sources. Yet, evidence for the ability of common edible elements to modulate Ab
oligomerization remains an unmet challenge. Here we identify a natural substance, based on cinnamon extract (CEppt),
which markedly inhibits the formation of toxic Ab oligomers and prevents the toxicity of Ab on neuronal PC12 cells. When
administered to an AD fly model, CEppt rectified their reduced longevity, fully recovered their locomotion defects and
totally abolished tetrameric species of Ab in their brain. Furthermore, oral administration of CEppt to an aggressive AD
transgenic mice model led to marked decrease in 56 kDa Ab oligomers, reduction of plaques and improvement in cognitive
behavior. Our results present a novel prophylactic approach for inhibition of toxic oligomeric Ab species formation in AD
through the utilization of a compound that is currently in use in human diet.
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Introduction
Alzheimer’s disease (AD) is a progressive, irreversible brain
disorder with an unclear etiology and no cure. Symptoms include
memory loss, confusion, impaired judgment, disorientation, and
loss of language skills [1]. In the past two decades, a large number
of experimental studies have established a pathological role for Ab
in AD [1–2]. However, recent debate has focused on whether Ab
amyloid fibrils or Ab soluble oligomers are the main neurotoxic
species which contribute to neurodegeneration and dementia.
Considerable evidence has indicated that amyloid fibrils are toxic
[1]. Yet, recent studies support the notion that it is actually the
early soluble oligomers that are the primary neurotoxic agents [3–
9]. In particular, 56 kDa (56*) dodecameric oligomers of Ab were
shown to correlated with the deterioration of cognitive functions in
AD model mice and their reintroduction into normal brains
resulted in memory impairment [7,10].
Despite a significant increase in our understanding of the
pathogenesis of AD, therapeutic options are still very limited and
aim only at amelioration of symptoms. More recent therapeutic
approaches aim at removing aggregated Ab and decreasing the
production of the pathogenic Ab42 peptide [11]. Yet, novel
observations suggest that the endogenous Ab peptides may
normally have a crucial role in activity-dependent regulation of
synaptic vesicle release [12], hence methods used to abolish all Ab
production may in fact aggravate synapse loss in Alzheimer’s
disease. Therefore, it may be advantageous to target the earliest
stages of Ab oligomerization, thus removing all potential toxic
species of Ab. Indeed, pervious work by our group and others has
already demonstrated that targeting the early process of Ab
molecular recognition is a very promising approach for the
treatment of AD [13–16].
Plants have a long history as a rich source of new bioactive
compounds for drug discovery and may have advantages in
relation to efficacy. Several reports documented the effectiveness
of herbal extracts over isolated material, in protection against lipid
peroxidation [17] and anti cancer effects [18]. For example, a
mixture of carotenoids have been found to be more effective than
any one single carotenoid in protecting liposomes against lipid
peroxidation [17].
Recent studies have shown inhibition of Ab plaque formation in
vitro and in vivo by compounds from natural sources [19–21]. Still,
evidence for the capability of common edible elements to inhibit
Ab oligomerization in vivo remains a challenge. Cinnamon is
widely used by humans, both as a spice and as a traditional
medicine. It is, perhaps, one of the oldest herbal medicines, having
been mentioned in the Bible (Exodus, Proverbs and Song of Songs) and
in Chinese texts as long as 4,000 years ago [22]. The unique
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as cinnamaldehyde, eugenol, cinnamyl acetate, and cinnamyl
alcohol, in addition to a wide range of other volatile substances
including safrole, coumarin and cinnamic acid esters [22].
Cinnamon has unique medicinal abilities such as blood sugar
control [23], anti-oxidant [22], anti inflammatory [24] and anti-
microbial activities [25]. Furthermore, it was demonstrated that
cinnamon has an inhibitory effect on Tau aggregation related to
AD [26], as well as pharmacological properties in the treatment of
type II diabetes [22]. Studies have shown that the potentially toxic
compounds in cinnamon bark are found primarily in lipid soluble
fractions but are present only in extremely low levels in water
soluble cinnamon extracts [27] which are therefore considered
highly safe for uptake. Here, we demonstrate the use of a natural
substance based on aqueous cinnamon extract (CEppt) as an
efficacious therapeutic agent that inhibits Ab oligomer formation
and ameliorates AD symptoms. In addition, we suggest the use of
an efficacious platform for screening molecules as AD drugs using
in vitro cell culture and in vivo AD fly and aggressive AD mouse
model.
Results
Inhibition of toxic Ab oligomer species and fibrils
formation
CEppt was initially tested for its ability to inhibit Ab42 oligomer
formation using the protocol established by Barghorn and
coworkers, which results in the formation of SDS stable off-
pathway oligomers [10]. The active fraction (CEppt) was isolated
as described previously [28]. Briefly, cinnamon bark was ground
into powder and the active fraction was extracted from the powder
into an aqueous phosphate buffer solution. CEppt fraction was
then precipitated from the cinnamon extract by KCl. Ab42 was
incubated with increasing concentrations of CEppt, and the
reaction mixtures were separated by SDS-PAGE followed by
western blot analysis using a specific anti Ab antibody (6E10)
(Figure 1A). The results revealed a dose dependent inhibition of
oligomer formation, where a low concentration ratio of 1:1
(CEppt: Ab42) showed total abolishment of the 56 kDa (56*)
neurotoxic oligomer and an increase in the level of monomers. It
seems that CEppt prevents the monomers and the early nontoxic
intermediate oligomers (,18 kDa) from further growing into the
toxic 56 kDa oligomers. Furthermore, we aimed to determine the
ability of CEppt to inhibit on-pathway Ab oligomer formation. For
that purpose Ab42 was dissolved in DMSO followed by dilution
with PBS to a final concentration of 0.4 mg/ml. The solution was
incubated at 37uC and samples were taken after 1, 3 and 6 hours
for evaluation in SDS gel. The results present a similar pattern of
inhibition as was the outcome of the off-pathway experiment
(Figure S1).
The debate regarding the comparative contribution of Ab
oligomers and fibrils to the pathogenesis of AD has not yet
resolved, we therefore wanted to examine whether CEppt may
inhibit the formation of Ab fibrils as well as that of oligomers. We
monitored the ability of Ab40 to form amyloid fibrils in the
presence or absence of CEppt for nine days using the Thioflavin-T
(ThT) binding assay. While the solution of Ab40 alone displayed a
lag-time of about 50 hours, the lag-time of the solution containing
CEppt: Ab at concentration ratios (w/w) of 5:1, 1:2, 1:20 was
significantly longer (Figure 1B). Moreover, relative to the maximal
fluorescence intensity reached for Ab40 alone, the maximal
fluorescence intensity measured for the samples containing 5:1,
1:2 (CEppt: Ab showed 100% inhibition of Ab40 fibrillization
(Figure 1C). From the ThT experiment an IC50 of 0.7 mg/ml was
calculated (Figure S2).
The inhibition of Ab42 fibrillization by CEppt was also tested.
Ab42 peptide is the major component of senile plaque and the ratio
of Ab42/Ab40 has been found to be increased in AD patient’s
brains [29–30]. Similar to the results using Ab40, CEppt in the
highest concentration was able to totally abolish fibril formation,
while lower concentrations showed a tenfold decrease in CEppt’s
ability to inhibit the fibrillization of Ab42 compared to Ab40
(Figure S3). The slightly decreased inhibition ratio of CEppt may
be a result of the high propensity of Ab42 to rapidly aggregate in
vitro [31].
As an additional measure for estimating the effect of CEppt on
Ab fibril formation, samples were taken from the ThT experiment
(Figure 1B) after nine days of incubation and were examined by
transmission electron microscopy (TEM). While the fibrils formed
by Ab alone were abundant, large, broad ribbon-like (Figure 1D),
the fibrils formed by the Ab in the presence of 1 mg/ml CEppt
(CEppt: Ab40, 1:20) were of a smaller diameter and length, and
were found at lower frequency (Figure 1E). Moreover, samples
containing 10 mg/ml of CEppt (CEppt: Ab40, 1:2), and 100 mg/ml
(CEppt: Ab40, 5:1) were devoid of fibrils and contained only small
amounts of truncated fibrils (Figure F–G). These results are highly
correlated with the ThT assay results.
Inhibition/disassembly of an ongoing process of Ab
fibrillization
Presently, AD diagnosis is based on cognitive and behavioral
symptoms. As these symptoms emerge relatively late in disease
progression, current therapeutic intervention begins after signifi-
cant neurodegeneration has occurred, thereby limiting its efficacy.
Therefore, we tested whether CEppt could inhibit an ongoing
process of Ab40 fibrillization. To that end, a second kinetic
experiment was performed, in which 100 mg/ml of CEppt was
added at three different time points during the nine day period of
fibrillization (0, 24 and 72 hours). Even after 72 hours, during
which the process of fibrillization has already reached a plateau
(Figure 1H), the addition of CEppt completely eliminated the
fibrils and only a limited number of amorphous plaques were
detected (Figure 1I–L).
CEppt inhibits the cytotoxic effect of Ab towards
cultured cell line
We next examined whether CEppt could inhibit Ab-mediated
cytotoxicity on the rat neuronal PC12 cell line. A control
experiment showed that on its own, CEppt is not toxic to the
cultured cells up to a concentration of 1 mg/ml (Figure S4 A, ref
CEppt). In contrast, Ab42 fibrils taken at the end of the ThT
experiment (Figure S3) were highly toxic to these cells (Figure 2A).
Remarkably, when incubated with Ab42 fibrils, CEppt displayed a
dose dependent inhibition of the cytotoxic effect of Ab42 fibrils,
with cell viability restored to 100% at CEppt: Ab40 concentration
ratio of 2:1 (Figure 2A). Similar results were obtained when Ab40
fibrils (Figure S4 A) and Ab42 oligomers (Figure S4 B) were used,
where very low CEppt’s concentration exhibit total viability
restoration of the cells.
The effect of CEppt in an in vivo transgenic fly system
While CEppt exhibited dramatic abilities in the in vitro
experiments, we wished to examine the effect of CEppt in vivo,
by using a Drosophila melanogaster model. This model of transgenic
flies express the human Ab42 protein in their nervous system, via
the Gal4-UAS system [32]. Crossing male flies carrying the pan-
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PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e16564Figure 1. Inhibition and disaggregation of Ab assemblies in vitro. (A) Determination of a dose-dependent effect of CEppt on soluble off-
pathway oligomer formation. Soluble oligomers were prepared [10] with and without increasing concentration of CEppt. Concentration ratios (w/w)
of CEppt: Ab42 are indicated. The control is Ab42 (0.6 mg/ml) alone. (B) The kinetics of Ab40 (20 mg/ml) fibril formation with and without the inhibitor
as assessed by the Thioflavin-T biding assay over the course of 264 hours. Concentrations are expressed as CEppt: Ab40 concentration ratio (w/w).
Control - Ab40 only (&); 5:1 (*); 1:2 (o); 1:20 (.); 1:200 (N); 1:2000 (c). (C) Endpoint of ThT analysis measurement T=264 hours. Concentrations are
expressed as CEppt: Ab40 concentration ratio (w/w), control is Ab40 (20 mg/ml). (D–G) Transmission electron microscope images taken from ThT
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carrying the UAS-regulated Ab42 transgene results in AD flies
expressing Ab42 in their nervous system. Characteristic symptoms
of these flies include impaired locomotion and memory, which
decline with age, as well as markedly reduced longevity [32]. We
fed flies either on regular Drosophila medium or medium
supplemented with 0.75 mg/ml CEppt from the beginning of
their larval stage through adulthood, and each class of adult
offspring was monitored daily for survival and locomotion
(climbing) ability [16,32–33]. As reported, flies expressing Ab42
showed a markedly reduced life span (16 days) compared to the 25
days of control flies (offspring that carried the Ab42 transgene but
did not express it because they lacked the Gal4 driver) (Figure 2B).
The CEppt diet rectified the reduced longevity of the AD flies to a
level that was not statistically different from that of the control flies
(Pv=0.0005) (Figure 2B). In contrast, CEppt had no significant
effect on the life span of the controlflies. CEppt also ameliorated the
locomotive defects of the AD flies. While the control flies showed
above90%climbingabilityat days 4–10,ADfliesstruggledto climb
up the test tube, showing only 30%–60% climbing ability
(Figure 2C). In contrast, AD flies fed with CEppt displayed climbing
ability almost identical to the control flies (Figure 2C), while no
effect of CEppt was observed on locomotion of the control flies at all
days tested. Two- tail ANOVA statistics showed Pv=0.0001 for all
four classes. These results show a specific and marked phenotypic
recovery of the AD flies fed with CEppt diet.
To Further estimate the therapeutic ability of CEppt on AD
flies, Ab was extracted from fly brains over expressing the Arctic
(Arc) (E22G) mutant form of Ab, which is associated with
enhanced Ab protofibrils formation and early-onset familial AD
[34]. These flies exhibited reduced life span and deficient
locomotion as described above for Ab42-expressing flies [16,32].
Low molecular species of Ab were detected in the soluble fraction
of extracts from AbArc42-expressing flies following immunopre-
cipitation with 6E10 followed by western blot. The results revealed
that monomers of Ab were not detectable in the wild type
(Oregon-R) control flies (non transgenic flies that have the same
genetic background as our Alzheimer’s flies). In contrast, in the
head extracts of CEppt-treated flies, Ab monomers were detected
and their level was increased by 20% in comparison to the non-
treated AbArc42-expressing flies (Figure 2D). Moreover, Ab
tetramers that were present in non-treated AbArc42 flies [16,32]
were absent from extracts of flies fed with CEppt (Figure 2D).
The effect of CEppt in an in vivo transgenic aggressive
mice model
We further examined the in vivo effect of CEppt on an aggressive
AD mouse model [35]. The commonly used transgenic AD mice
harbor three familial AD mutations [36], and have served as useful
model for studying Ab deposition, amyloidogenesis and the
cognitive impairment associated with AD neuropathology. Yet,
the majority of AD mice fail to develop the characteristic paired
helical filaments that comprise the neurofibrillary tangles of AD
and, importantly, do not show the characteristic overt neuronal
loss in brain regions most affected in AD patients. Therefore, in
this work we used an aggressive AD mouse model that displays the
majority of AD symptoms. These transgenic mice co-express a
total of five familial AD mutations (‘‘5XFAD’’) and display early (2
months) plaque formation, impaired cognition (4 months), and
neuronal cell death (9 months) [35]. Mice were continuously
administered with CEppt in the drinking water (100 mg/ml) from
the age of two month for 120 days, and then mice were analyzed
for changes in cognitive abilities, presence of oligomers and plaque
loads. A new object recognition test [37], performed at the age of
180 days, revealed a significant improvement of memory in the
CEppt-treated 5XFAD group compared to the untreated group
(Pv=0.034) (Figure 3A). Moreover, the cognitive performance of
5XFAD mice treated with CEppt was almost identical to non-
transgenic mice having the same genetic background. This result
does not reflect an effect on motor functions since there was no
statistical difference in the ability of the 5XFAD treated and
untreated mice to perform the rotarod test (data not shown). These
results suggest that CEppt may have cured the defective cognition
of the 5XFAD mice.
Following the behavioral assays, the animals were sacrificed and
soluble and insoluble Ab fractions were extracted from hemi-
brains. Treatment with CEppt led to a remarkable reduction of
60% in the level of the 56 kDa toxic Ab oligomer (Pv=0.0011)
(Figure 3B–C) compared to the untreated 5XFAD mice. This is
the first demonstration for the ability of a natural compound to
reduce the formation of the toxic 56 kDa species in an intact
animal. In addition, significant reduction was observed in the
number and mean size of Ab plaque cores in the corresponding
5XFAD hemi-brains. Frontal sections of the hippocampus treated
vs. untreated mice were stained with the Ab-specific 6E10
antibody and revealed a reduction of 42% in plaque load
following treatment with CEppt (Pv=0.0043) (Figure 4A–B, E).
Furthermore, when stained with Congo red, a specific amyloid-
binding dye, a 63% reduction in amyloid plaques was observed
(Pv=0.034) (Figure 4C–D, F). Ab reduction of about 35% was
calculated from the total insoluble Ab fraction as determined by
western blot analysis (Pv=0.021) (Figure 3D). Taken together,
these results suggest that treatment with CEppt reduced Ab
deposition and improved cognitive function in 5XFAD mice.
Discussion
AD is the most common cause of late-life dementia and a
leading cause of death in the western world. While the etiology of
AD is not fully understood, compelling evidences has accumulated
over the past few years for a correlation between soluble Ab and
the extent of synaptic loss and cognitive impairment [1,4,6–8].
Thus, it appears that the most promising strategy for developing
therapeutic agents to treat AD and other amyloid-associated
diseases is by targeting the early molecular recognition and self-
assembly processes [14,16].
Here, we have identified a novel herbal substance, based on
aqueous cinnamon extract (CEppt) that can serve as an efficacious
inhibitor of both the oligomerization and fibrillization of Ab in vitro
and in vivo. In contrast to the raw cinnamon bark, which is
considered to have hepatotoxic effects [27], our method of
preparation results in a highly potent non-toxic compound which
is easily manufactured at low cost.
Pervious studies have already demonstrated the powerful usage
of herbal extract in arresting amyloid fibrils. Examples for
extensively studied naturally occurring compounds are the (-)-
analysis after 264 hours. (D)Ab40 alone, (E) CEppt:Ab40 (1:20), (F) CEppt:Ab40 (1:2), (G) CEppt:Ab40 (5:1), (H) Samples of Ab40 (20 mg/ml) was incubated
alone (&) or with the addition of CEppt (100 mg/ml) at various time points of Ab aggregation,Ab aggregation was monitored by ThT assay. CEppt
was added at 0 hour (b); 24 hours (N) and 72 hours (.). (I–L) Transmission electron microscope of samples taken from the disaggregation assay after
200 hr. (I) Ab40 alone, (J) T=0 hour, (K) T=24 hours, (L) T=72 hours.
doi:10.1371/journal.pone.0016564.g001
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which is derived from the natural turmeric. Both EGCG and
Curcumin have been reported in several studies as a potential
neuroprotective strategy for neurodegenerative disorder such as
AD and Parkinson disease (PD) [38–39]. Yet, to the best of our
knowledge, no study has yet demonstrated the ability of a natural
substance to reduce the level of toxic 56 kDa oligomers, which are
thought to be a major neurotoxic species of Ab [7,10].
In order to determine the pattern of inhibition and to
understand which phase of the amyloidogenic process is inhibited
by CEppt, we performed various analyses and followed the kinetics
of amyloid fibrils formation and their morphology. CEppt
changed the shape of the nucleation curve, causing a longer lag-
phase and a considerably lower amount of amyloid fibril formation
(Figure 1B–G, Figure S3). In addition, we demonstrated that
CEppt stabilizes the non-toxic early off- pathway oligomers and
prevents their further assembly into the toxic 56 kDa oligomer
species (Figure 1A), as well as inhibiting the early formation of on-
pathway oligomer assemblies (Figure S1). Furthermore, we found
that CEppt can arrest an ongoing process of Ab fibrillization and
to disassemble preformed fibrils, a characteristic which is very
important when dealing with neurodegenerative disorders whose
symptoms emerge relatively late in the disease progression when
fibrils have already begun to form. Importantly, the inhibitory
effects of CEppt on Ab assembly in vitro correlate well with its
effects in vivo, where CEppt completely alleviated Ab-engendered
symptoms in transgenic fly and mice models of AD.
In contrast to the majority of AD transgenic mice models, in
which formation of amyloid plaques takes about 6–12 months
[36], we used an aggressive 5XFAD mice [35]. These model mice
Figure 2. CEppt alleviates toxic effects of Ab – cell and fly assays. (A) Samples of Ab42 (20 mg/ml) with or without various concentrations of
CEppt were incubated for 24 hours with PC12 cells culture. To exclude any toxic effect of CEppt, CEppt alone (9 mg/ml) was pre-incubated for 24
hours with PC12 cells (ref CEppt). Cells viability was determined using MTT viability assay. ** Pv,0.005. (B) The effect of CEppt on longevity of Ab42-
expressing flies. The life span of four classes of flies was evaluated. AD flies grown on regular medium (black line), AD flies grown on medium
containing CEppt (black dashed line), Control Flies (carrying the Ab42 transgene but not expressing it) grown on regular medium (grey line), Control
Flies (carrying the Ab42 transgene but not expressing it) grown on medium containing CEppt (grey dashed line). (C) The effect of CEppt on the
climbing behavior of Ab42-expressing flies. Four classes, each containing six-nine vials with 10 flies in each: AD flies grown on regular medium
(black),AD flies grown on medium containing CEppt (grey), Control flies (carrying the Ab42 transgene but not expressing it) grown on either regular
medium (striped) or on medium containing CEppt (white), were analyzed using the climbing assay. Results show the percent of flies climbing to the
top of the vial after 18 seconds, during the course of 10 days. Pv,0.0001. (D) Head extract from 4 days old flies. OR-control flies (left), AbArc42-
expressing flies unfed (middle) fed with 0.75 mg/mL CEppt (right) (n=40 in each group). Accumulation of Ab tetramers is evident only in AbArc42 flies
which were not fed with CEppt.
doi:10.1371/journal.pone.0016564.g002
Figure 3. The effect of CEppt on cognitive performances and Ab oligomer formation in 5XFAD Alzheimer’s disease model mice. (A)
Object recognition test of transgenic AD model mice (5XFAD), non-transgenic littermate (W.T.), and 5XFAD treated mice. Placebo 5XFAD mice were
given drinking water (n=8); W.T mice were given drinking water (n=8); treated 5XFAD mice were given water with CEppt (100 mg/ml) (n=7). One-
way ANOVA tests show Pv=0.0413. (B) Soluble fraction of mouse brain homogenates were analyzed by western blot probed with Ab antibody 6E10.
(C) Western blot band signals for 56 kDa in (B) were quantified using densitometry and displayed as Percent of 56 kDa toxic oligomer band intensity.
(D) Insoluble fraction of mouse brain homogenates were analyzed by western blot probed with Ab antibody 6E10, quantified using densitometry,
and displayed as relative intensities of total Ab signals.
doi:10.1371/journal.pone.0016564.g003
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month), and exhibit intraneuronal Ab42, neurodegeneration and
neuronal loss[35]. These characteristics could be a disadvantage for
evaluating drug candidates that are moderately efficacious and
could be overlooked when tested in such an aggressive model, as
opposed to the common more moderate models which may
recapitulate the slower progression of AD in humans. However, the
fact that CEppt caused a significant reduction of the amount of
amyloid deposits and of the soluble 56 kDa toxic oligomer in the
brains of the 5XFAD mice, and dramatically improved their
cognitive performance suggests that CEppt may be likewise effective
in the more typical AD mice models and in human patients.
Several reports have indicated the presence of polyphenol in the
cinnamon extract [27,40]. Moreover, several studies have shown
that polyphenols can inhibit the aggregation of various amyloido-
genic peptides [41–43]. We hypothesize that CEppt may interacts
with the Ab peptide at a very early stage of its self assembly
through the polyphenol entity to inhibit its aggregation, thereby
preventing the Ab- mediated toxicity.
Although these results clearly show the ability of CEppt to
inhibit the progress of Ab aggregation, it is important to note that
the mechanism of action remains to be elucidated. Moreover, in
this work, the ability of CEppt to cross the BBB was not tested. It is
possible that several active molecules in CEppt or their derivatives
may cross the BBB, yet it is possible that CEppt possess a
peripheral mode of therapy. Since CEppt is comprised of several
molecules, characterizing the active compound and understanding
the mechanism of action will require further work.
To conclude, we have identified a novel prophylactic approach
for AD, utilizing a natural substance, which is currently very
common in human diet. The CEppt fraction is orally bioavailable
and very safe in vitro and in vivo. We demonstrated that a minimal
concentration of CEppt is capable of inhibiting the formation of
both Ab toxic oligomer species and amyloid fibrils in both the test
tube and in the intact animal, and can correct the cognitive
impairment in AD animal models. The agreement between the
results obtained in vitro, in cultured cells, in flies and in mice
suggests that together they can be used as an efficient platform for
screening molecules as drugs for the treatment of AD. Moreover,
we believe that the CEppt, which has a unique herbal supplement
profile of actions with multiple components, would have an
advantage over crystal-purified drugs containing only a single
component, and could be developed as novel precluding, easy to
administer, prophylactic treatment of AD pathogenesis.
Materials and Methods
Ethics Statement
The mice were housed and maintained in the animal facility of
Tel Aviv University, and all experiments were in compliance with
protocols approved (Permit Number is: L-10-027) by the TAU
animal care committee.
Cinnamon extract
Cinnamon bark was ground into powder using a coffee grinder.
The active material was extracted from the powder into an aqueous
phosphate buffer solution 0.02 M, pH 7 overnight and centrifuged.
The supernatant was kept at 4uC until use. CEppt fraction was then
precipitated from the cinnamon extract (CE) by KCL 0.3 M and
dissolved in 0.02 M phosphate buffer, pH 7, or in water, as needed.
Ab solution
Synthetic lyophilized Ab40 or Ab42 (Bachem, Bubendorf,
Switzerland) was dissolved in dimethylsulfoxide (DMSO) to a
concentration of 0.4 mg/ml and sonicated in ice water for 20 sec
to avoid pre-aggregation. Ab solutions were prepared by
immediate dilution with 10 mM phosphate-buffered saline (100
mM NaCl, 0.5 mM EDTA, pH 7.4) to a concentration of 40 mg/
ml and further diluted with CEppt solution to final concentration
of 20 mg/ml (containing 5% (v/v) DMSO).
Thioflavin T binding fluorescence
CEppt was dissolved in ddH2O to a concentration of 10 mg/ml
and then diluted with 10 mM PBS buffer, (100 mM NaCl, 0.5 mM
EDTA, pH 7.4) to a final concentration of (0.01 mg/ml–1 mg/ml).
40 mg/ml Ab40 or Ab42 solution was immediately mixed with the
cinnamon solutions to final concentration of 20 mg/ml Ab and
various cinnamon concentrations (0.01 mg/ml–100 mg/ml). The
samples were incubated at 37uC and the fibrillogenesis rate was
monitored using ThT fluorescence analysis. The respective
excitation and emission wavelengths were 450 nm, 2.5 nm slit,
and at 480 nm, 5 nm slit. A 10-fold diluted sample was taken and
mixed with 900 ml ThT 0.4 mM. The fluorescence of ThT was
measured using a Jobin Yvon Horiba Fluoromax 3 fluorimeter.
Each experiment was repeated in quadruplicate.
Disaggregation assay
Synthetic lyophilized Ab40 (Bachem, Bubendorf, Switzerland)
was dissolved in dimethylsulfoxide (DMSO) to a concentration of
0.4 mg/ml and sonicated in ice water for 20 sec to avoid pre-
aggregation. Ab solution was prepared by immediate dilution with
10 mM phosphate-buffered saline (100 mM NaCl, 0.5 mM
EDTA, pH 7.4) to a final concentration of 40 mg/ml (containing
10% DMSO). CEppt was dissolved in ddH2O to a concentration
of 200 mg/ml and then diluted with the Ab solution to a final
concentration of 100 mg/ml, same amount of ddH2O was added
to the W.T sample as a reference. The CEppt was added at
various time points- 0 hour, 24 hours and 72 hours. Samples were
monitored using ThT assay as describe above.
Transmission electron microscopy
10 ml from different ThT fluorescence samples were placed on
400 mesh copper grids covered by carbon-stabilized Formvar film
(SPI Supplies, West Chester, PA). After 1.5 minutes, excess fluid
was removed, and the grids were negatively stained with 10 mlo f
2% uranyl acetate solution for 1.5 min. Finally, excess fluid was
removed and the samples were viewed in a JEOL 1200EX
electron microscope operating at 80 kV.
Determination of off-pathway soluble oligomer
formation
Ab42 intermediates and toxic oligomers (56 kDa) were produced
according to Barghorn et al, 2005 [10]. To avoid pre-aggregation,
Figure 4. The effect of CEppt on Ab plaques formation in 5XFAD Alzheimer’s disease model mice. (A) Histological images of frontal
cortex sections stained with Ab antibody 6E10 from vehicle-treated 5XFAD mice, and (B) CEppt-treated 5XFAD mice. (C) Histological images of frontal
cortex sections stained with Congo red from vehicle-treated 5XFAD mice, and (D) CEppt-treated 5XFAD mice. Scale bar=100 mm. (E) Quantification of
the % plaque load area of hippocampal sections from 5XFAD mice with or without CEppt treatment determined by 6E10 staining. (F) Quantification
of the % plaque load area of hippocampal sections from 5XFAD mice with or without CEppt treatment determined by Congo red staining.
doi:10.1371/journal.pone.0016564.g004
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propanol (HFIP). Ab42 was dissolved in 100% HFIP, sonicated in
ice water for 20 seconds and incubated for 2 hours at 37uCu n d e r
shaking at 100 RPM. The inhibitor CEppt was dissolved in DMSO
to a concentration of 40 mg/ml, sonicated for 1 min and then diluted
in DMSO to several concentrations (1 mg/ml–20 mg/ml). After
evaporation in a speedVac, Ab42 was resuspended in DMSO(with or
without the CEppt in different concentrations) to 20 mg/ml and
diluted with PBS (20 mM NaH2PO4, 140 mM NaCl, pH 7.4) to a
final concentration of 2 mg/ml and 1/10 volume 2% SDS (final
concentration of 0.2%). The Ab toxic oligomers were generated by a
further dilution with H2O to final concentration of 0.6 mg/ml and
incubated for another 18 hours or more. Ab aggregation products
werethenseparatedusinga15%Tris-Tricinegelfollowedbywestern
blot analysis by a specific anti Ab antibody (6E10) (SIGNET).
Determination of on-pathway soluble oligomer
formation
To avoid pre-aggregation, synthetic lyophilized Ab42 was
dissolved in 100% HFIP, sonicated in ice water for 20 seconds
and incubated for 2 hours at 37uC under shaking at 100 RPM.
After evaporation in a speedVac, Ab42 was resuspended in DMSO
to a concentration of 9 mg/ml and then diluted with or without
CEppt at different concentrations to a final concentration of 0.4
mg/ml. The samples were incubated for 6 hours at 37uC. Ab
aggregation products were then separated using a 15% Tris-
Tricine gel followed by western blot analysis using a specific anti
Ab antibody (6E10) (SIGNET).
Cells cytotoxicity assay
PC12 pheochromocytoma cell line was routinely grown in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
8% Fetal Calf Serum, 8% horse serum, 100 U/ml penicillin, 100
U/ml streptomycin and 2 mM L-glutamine.
Sub-confluent cells were harvested by trypsinization, counted
and diluted in the cell media to 2610
4 cells/ml, then cultured in
96 wells plate (100 ml/well) and incubated over-night at 37uC. In
order to exclude the effect of the serum, the wells were washed
once with serum free-DMEM. Then, into each well added 100 ml
of DMEM with Ab40 or Ab42 fibrils 20 mg/ml previously
incubated with or without CEppt (as describes above) or Ab42
oligomers that were incubated previously with or without CEppt.
The Ab42 oligomers were first precipitated with acetone to exclude
toxicity of the SDS and HFIP from the oligomer preparation
protocol of Barghorn et al, [10]. Each treatment was performed in
four repeats. After 24 hr incubation at 37uC, cell viability was
evaluated using thiazolyl-blue-tetrazolium-bromide (MTT) assay.
Briefly, 20 ml of 5 mg/ml MTT dissolved in PBS were added into
each well. After 4 hr incubation at 37uC, 100 ml of extraction
buffer (20% SDS dissolved in 50% dimethylformamide and 50%
DDW solution, pH 4.7) were added into each well and the plates
were incubated again overnight at 37uC. Finally, color intensity
was measured using ELISA Reader at 570 nm.
Cells viability (%) = O.D. (570 nm) in the presence of Ab with
or without inhibitor*100, and O.D. (570 nm) when only inhibitor
was added.
Fly keeping
Flies were reared on standard corneal-molasses medium and
were kept at 25uC. As Drosophila females can store sperm cells in
their bodies, crosses were conducted using virgin females collected
no longer than 8 hours after eclosion at 25uC or 18 hours after
eclosion at 18uC. Adult offspring (F1) from the crosses were
collected up to 9 days after the beginning of their eclosion at 25uC
in order to avoid offspring from the next generation (F2).
Fly crossing
Male flies carrying the driver elav
c155-Gal4 (on their X
chromosome) were crossed with females carrying the Ab42
transgene (located on an autosome) under the UAS promoter in
a homozygous condition. This resulted in first generation (F1)
female offspring expressing Ab42 in their nervous system. They
served as our Alzheimer’s Drosophila model. Male F1 offspring,
which carried the Ab42 transgene but did not express it (because
they lacked the Gal4 driver) served as a control.
Special fly feeding
CEppt dissolved in ddH2O was added to standard corneal-
molasses medium about 10 minutes after cooking (0.75 mg/mL). The
compound was mixed thoroughly into the medium and the mixture
was aliquoted into rearing vials. The vials were kept at 4uCu n t i lu s e .
Crosses were performed either on regular Drosophila medium
( co n tr ol )oro nm ed iu ms u pp l em e n t edw it hCE p pt .A n im a l sf edo nt he
appropriate medium from the beginning of the larval stage onwards.
Longetivity assay
Flies expressing one copy of Ab42 reared at 29uC on medium
with or without CEppt were separated to four classes: 1. Females
expressing Ab42, on regular medium. 2. Females expressing Ab42,
on medium supplemented with CEppt. 3. Male controls (lacking
the Gal4 driver), on regular medium. 4. Male controls (lacking the
Gal4 driver), on medium supplemented with CEppt. For each
class, six plastic vials each with 10 flies were collected and fresh
food was given every three days (whether with or without CEppt).
The number of viable Ab-expressing and control flies treated with
and without CEppt was recorded daily post eclosion. Differences
in survival rates were analyzed using the SPSS 11 Kaplan-Meir
software package.
Locomotive (climbing) assay
Test tubes of each of the four classes mentioned above, each
containing 10 flies were tapped gently on the table and were let
stand for 18 seconds. The percent of flies which climbed to the top
of the test tube was then calculated over time. Each class had six
independent test tube repeats. Statistical analysis was done using
StatSoft Statistica 7, parametric ANOVA testing.
Immuno-precipitation and western-blot of fly head
extracts
Forty freshly decapitated heads from 4 day old OR-control,
AbArc-42 flies treated and non-treated with CEppt (as described
before) were collected and homogenized in 30 ml PBS/protease
inhibitor/1% SDS [16,32]. Homogenates were then centrifuged at
13,000 rpm for 25 seconds and the supernatant was further
immuno-precipitated with specific 6E10 anti-Ab antibody (1:10)
over night at 4uC. Samples were boiled for 6 minutes, and were
then western blotted and membranes were boiled in PBS for 10
minutes before antibodies were introduced. Total protein levels of
the samples were quantified using Bradford analysis and a total of
100 mg protein were loaded in each lane. Since samples were
loaded after IP with specific 6E10 anti-Ab antibody, no marker
protein levels could be measured.
Object recognition test
After 4 months of treatment with 100 mg/ml CEppt solution or
water, the mice were tested using a novel object recognition test
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interacting with the novel object [37]. Memory was operationally
defined by the discrimination index for the novel object (DI) as the
proportion of time the mice spent investigating the novel object
and the familiar one.
Immunohistology
6-month-old 5XFAD mice were sacrificed (transcardially
punctured and saline-perfused) and their brains rapidly excised
and frozen. The brains (left hemisphere) were cut in 14 mm
coronal brain sections, using cryostat at 220uC, and used for
histological examination. The slices were stained at Bregma
21.58 mm with Congo-Red staining [Sigma-C6767] and Anti Ab
(SIG-39320500 R&D) and visualized by fluorescence microscopy
for quantification of the amount of vascular amyloid depositions.
Quantification of hippocampus Ab burden was done in a blinded
fashion way using Imaging Research software from the NIH in an
unbiased stereological approach.
Soluble and insoluble Ab brain quantification
Right hemisphere of each mouse was homogenized in 1 ml
protease inhibitor dissolved in PBS. Homogenates were then
centrifuged at 113,000 g for 40 minutes at 4uC, and two fractions
were obtained: soluble and insoluble. The insoluble fraction was
dissolved in 1 ml 5 M Guanidine Hydrochloride, 50 mM Tris,
pH 8 and was incubated over night in room temperature with
gentle agitation. Soluble and insoluble fractions were then
quantified by Bradford reagent. An aliquot of each sample was
resolved by SDS-PAGE and transferred using standard semi-dry
conditions. Proteins were resolved by 12% SDS-PAGE and
transferred onto a 0.45 mm nitrocellulose membrane at 100 V for
30 min. (Bio-Rad) using a Semi-Dry Electroblotter (Bio-Rad).
After transfer, the membrane was blocked overnight in 5% (wt/
vol) nonfat dry milk in TBS-T (20 mM Tris, pH 7.4, 150 mM
NaCl, 0.1% (vol/vol) Tween 20) and washed 3 times for 10 min
each in TBS-T before and after adding the antibody. All
antibodies were diluted in 5% (wt/vol) nonfat dry milk in TBS-
T. The membrane was incubated with 6E10 antibody (1:1000)
(SIGNET) for 2 h at room temperature. After wash with TBS-T,
the blots were incubated with Anti-Mouse HRP secondary
antibodie (1:10,000) (Jackson immunoresearch laboratories) for
1 h at room temperature and developed with enhanced chemi-
luminescence (ECL) reagents (Pierce). The protein band was
visualized using X-ray film. Gels were analyzed using densitometry
and bands were normalized to Actin.
Statistical Analysis
Data comparisons were performed using the Student’s t test
when two groups were compared or one-way ANOVA analysis of
variance when three or more groups were analyzed. A P value of
,0.05 was considered significant. *, Pv,0.05, **, Pv,0.005.
Supporting Information
Figure S1 Determination of a dose-dependent effect of
CEppt on on-pathway Ab42 soluble oligomer formation.
Soluble oligomers were prepared with or without increasing
concentration of CEppt. Concentration ratios (w/w) of Ab42:
CEppt are indicated. The control is Ab42 0.4 mg/ml alone.
Samples were loaded on SDS gel after 1, 3 and 6 hours followed
by western blot with 6E10. By 1 hour concentration ratios of 1:2
and 1:1 (Ab42: CEppt) could dramatically inhibit the higher MW
oligomers (,60–80 kDa) while increasing the level of monomers
and low MW oligomers (4–10 kDa). At lower concentration ratios
of 2:1 and 4:1 (Ab42: CEppt) the formation of higher MW
oligomers was still inhibited while the level of the monomers and
low MW oligomers was decreased, yet an increment of
intermediate oligomers (15–20 kDa) was observed. By 3 hours
the monomers were less affected but there still was a very
efficacious inhibition of the higher MW oligomers while the
intermediate oligomers were increased at ratios of 1:2 and 1:1
Ab42: CEppt. By 6 hours the main species that were inhibited were
high MW and protofibrils.
(PDF)
Figure S2 Concentration-dependent inhibition of Ab40
fibrillogenesis. CEppt was added at different concentrations to
a fixed amount of 20 mg/ml Ab40. After incubation for 264 hours
at 37uC, ThT fluorescence was monitored at an emission
wavelength of 480 nm (excitation at 450 nm).
(PDF)
Figure S3 Inhibition of Ab42 assemblies in vitro. (A) The
kinetics of Ab42 (20 mg/ml) fibril formation in the absence or
presence of CEppt as assessed by the Thioflavin-T binding assay
over the course of 312 hours. Concentrations are expressed as
CEppt:Ab42 concentration ratio (w/w). Control - Ab42 only (&);
5:1 (*); 1:2 (o); 1:20 (m); 1:200 (-); 1:2000 (N). (B) Endpoint of ThT
analysis measurement T=312 hours. Concentrations are ex-
pressed as CEppt: Ab42 concentration ratio (w/w), control is Ab42
(20 mg/ml).
(PDF)
Figure S4 CEppt alleviates toxic effects of Ab oligomers
and fibrils in cell assay. (A) Samplesof Ab40(20 mg/ml)with or
without various concentrations of CEppt were incubated for 24
hours with PC12 cells culture. To exclude any toxic effect of CEppt,
CEppt alone (1 mg/ml) was pre-incubated for 24 hours with PC12
cells (ref CEppt). Cells viability was determined using MTT viability
assay. (B) Samples of Ab42 oligomers (0.6 mg/ml) with or without
various concentrations of CEppt were incubated for 24 hours with
PC12 cells culture. To exclude any toxic effect of CEppt, CEppt
alone at the highest concentration was pre-incubated for 24 hours
with PC12 cells (ref CEppt). Cells viability was determined using
MTT viability assay. * Pv, 0.05, ** Pv,0.005.
(PDF)
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